Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

Merck + Co., Inc.

Merch Sharp & Dohme Ltd

Dohme Ltd.

Merck Sharp

Neil Roy Curtis

Janusz Jozef Kulagowski

Raymond Baker

Christopher John Swain

Brian John Williams

Jason Matthew Elliott

Gregory John Hollingworth

Philip Stephen Jackson

Timothy Harrison

Nadia Melanie Rupniak

Eileen Mary Seward

Mark Peter Ridgill

Paul D Leeson

Paul David Leeson

Mark Stewart Chambers

Adrian Leonard Smith

Eileen May Seward

Robert James Maxey

Ian Thomas Huscroft

Nigel J Liverton

Angus Murray MacLeod

Christopher F Claiborne

Andrew Pate Owens

Martin Richard Teall

Tamara Ladduwahetty

Kevin John Merchant

Kevin William Moore

Francine Sternfeld

Mark Stuart Chambers

Helen Jane Szekeres

Howard Barff Broughton

Ian M Mawer

Piotr Antoni Raubo

Peter Alan Hunt

Alexander Charles Humphries

Helen Jane Bryant

Myra Gilligan

Brian E Libby

Angus Murray Macleod

Emanuela Gancia

Compounds of formula (I) are potent and selective 5-HTantagonists, useful in treatment of a variety of adverse conditions of the CNS. 

[object Object]

Substituted carbocyclic sulphonamide derivatives of formula (I), in which n is 0 or 1 and the other variables are as defined in the claims, are selective 5-HTreceptor antagonists and are thereby effective in the treatment of a variety of neurological conditions, including depression and sleep disorders. 

Compounds of formula I: are antagonists of the human 5-HTreceptor, and hence useful in treatment or prevention of a variety of neurological conditions.

Azabicyclic ether derivatives and their use as therapeutic agents

A class of 1,2,3a,4,x-pentaaza-cyclopenta&lsqb;a&rsqb;naphthalene compounds (x&equals;6, 7, 8 or 9) is described. The compounds have a high affinity for the GABA &agr;5 receptors and show inverse agonist activity thereat. The compounds are useful in therapy where cognition enhancement is required.

Pentaaza-cyclopental&lsqb;a&rsqb;naphthalene derivatives as ligands for GABAa &agr;5 receptors

The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

Use of NK-1 receptor antagonists for treating major depressive disorders

Tetrahydroindolone derivatives as gabaaalpha5 ligands for enhancing cognition

Aryl amidines, compositions containing such compounds and methods of use

The present invention provides methods for the treatment or prevention of cognitive disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

Use of NK-1 receptor antagonists for treating cognitive disorders

The present invention is directed to substituted spiro-azacyclic derivatives of the formula (I):

Spiro-azacyclic derivatives and their use as therapeutic agents

The present invention provides methods for the treatment or prevention of major depressive disorder with anxiety without concomitant therapy with other anti-depressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

The present invention provides a method for the treatment or prevention of schizophrenic disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

Use of NK-1 receptors antagonists for treating schizophrenic disorders

The present invention provides methods for the treatment or prevention of amnestic disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.

Use of NK-1 receptor antagonists for treating amnestic disorders

The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant therapy with other anti-stress agents, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.

Use of NK-1 receptor antagonists for treating stress disorders

Spiro-piperidine derivatives and their use as therapeutic agents

Growing community of inventors

Puckeridge, United Kingdom

Neil Roy Curtis